http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1367970-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a924bb4436aaecd1aaf70f564c601ad4 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
filingDate | 2002-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08891d0ae08115d269e84556d4e9bf97 |
publicationDate | 2003-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1367970-A1 |
titleOfInvention | Alkyl aryl polyether alcohol polymers for improvement of nasal breathing |
abstract | A method and composition for treatment and prophylaxis of snoring, sleep apnea or sudden infant death syndrome and for improvement of nasal breathing in mammals by nasal and/or pharyngeal administration of tyloxapol or a related alkylaryl polyether alcohol polymer. A spray, liquid or solid composition comprising from about 0.01 to about 20 % (w/v), equivalent to about 100 νg/ml to about 200 mg/ml, or tyloxapol or another alkylaryl polyether alcohol polymer alone or in admixture with pharmaceutically acceptable excipients and additives. The composition is administered as a spray, liquid, liquid drops, lozenges or powder suitable for nasal and/or pharyngeal application. |
priorityDate | 2001-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.